Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Traditional Chinese Medicine Holdings Co (OTCPK:CHIZF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Traditional Chinese Medicine Holdings Co EBITDA Margin % Related Terms
China Traditional Chinese Medicine Holdings Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Traditional Chinese Medicine Holdings Co EBITDA Margin % Chart
China Traditional Chinese Medicine Holdings Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Traditional Chinese Medicine Holdings Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Traditional Chinese Medicine Holdings Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Traditional Chinese Medicine Holdings Co (CHIZF) has a EBITDA Margin % of -3.36% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Traditional Chinese Medicine Holdings Co and its competitors. According to the industry distribution chart, China Traditional Chinese Medicine Holdings Co ranks #737 out of 961 companies in the Drug Manufacturers industry, placing it in the top 76.7%.
Is China Traditional Chinese Medicine Holdings Co's EBITDA Margin % too high?
China Traditional Chinese Medicine Holdings Co's current EBITDA Margin % is -3.36%. Based on the distribution chart, China Traditional Chinese Medicine Holdings Co ranks #737 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Traditional Chinese Medicine Holdings Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Traditional Chinese Medicine Holdings Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Traditional Chinese Medicine Holdings Co ranks #737 out of 961 companies for EBITDA Margin %. This places China Traditional Chinese Medicine Holdings Co in the lower half of its industry. The industry median EBITDA Margin % is 12.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Traditional Chinese Medicine Holdings Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Traditional Chinese Medicine Holdings Co's current EBITDA Margin % is -3.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Traditional Chinese Medicine Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, China Traditional Chinese Medicine Holdings Co (CHIZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.36, compared to a current price of $0.16 — trading 54.7% below its estimated fair value. The current EBITDA Margin % is -3.36%. China Traditional Chinese Medicine Holdings Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Traditional Chinese Medicine Holdings Co (CHIZF), the current EBITDA Margin % is -3.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Traditional Chinese Medicine Holdings Co (CHIZF) Overvalued in 2026?
Based on GuruFocus' analysis, China Traditional Chinese Medicine Holdings Co stock appears to be undervalued.
The current stock price of $0.16 is trading 54.7% below its estimated GF Value™ of $0.36.
GuruFocus considers China Traditional Chinese Medicine Holdings Co to be Possible Value Trap.
Key valuation signals for CHIZF:
EBITDA Margin %: -3.36%
GF Value™: $0.36 vs. price of $0.16 (54.7% below fair value)
No single metric tells the full story. See the CHIZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries.
42GF Score
Get the complete analysis for CHIZF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIZF has been successfully added to your 
